FDA approves reagents for evaluating risk of cardiovascular disease

被引：0

|

作者：

不详

机构：

来源：

BIOTECHNOLOGY LAW REPORT | 1997年 / 16卷 / 5-6期

关键词：

atherosclerosis; Hemagen diagnostics;

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

收藏

页码：553 / 553

页数：1

相关论文

共 50 条

[1] FDA approves blood test for heart disease risk
不详
LABORATORY MEDICINE, 2003, 34 (09) : 629 - 629
[2] Wegovy: FDA approves weight loss drug to cut cardiovascular risk
Tanne, Janice Hopkins
BMJ-BRITISH MEDICAL JOURNAL, 2024, 384 : q642
[3] FDA Approves Semaglutide to Reduce Risk of Kidney Disease Progression
Anderer, Samantha
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2025, 333 (13):
[4] FDA approves canaglifl ozin to reduce risk of diabetic kidney disease
不详
NURSE PRACTITIONER, 2020, 45 (02): : 56 - 56
[5] FDA approves vaccine for Lyme disease
不详
BRITISH JOURNAL OF OPHTHALMOLOGY, 1999, 83 (04) : 389 - 389
[6] FDA approves Onsolis with risk reduction plan
Reactions Weekly, 2009, 1262 (1) : 2 - 2
[7] FDA approves drug for women at cancer risk
Woodman, R
BRITISH MEDICAL JOURNAL, 1998, 317 (7168): : 1274 - 1274
[8] FDA approves first treatment for Fabry disease
不详
LABORATORY MEDICINE, 2003, 34 (06) : 429 - 430
[9] FDA approves new drug for Alzheimer disease
不详
NURSE PRACTITIONER, 2021, 46 (09): : 56 - 56
[10] FDA approves galantamine for Alzheimer's disease
不详
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2001, 58 (08) : 649 - 649

← 1 2 3 4 5 →